What is the primary driver behind the significant decrease in net income for the first nine months of 2005 compared to 2004?

The primary driver for the 29% decrease in net income for the first nine months of 2005 was a substantial $1.07 billion pre-tax charge recorded in the second quarter related to a master settlement agreement for the majority of U.S. Zyprexa product liability claims. This charge, along with other factors, significantly impacted the year-to-date profitability.

How is Eli Lilly managing the ongoing legal challenges, particularly concerning Zyprexa?

Eli Lilly has entered into a master settlement agreement to resolve the majority of U.S. Zyprexa product liability claims for approximately $700 million. The company is also actively defending against generic manufacturers challenging Zyprexa patents and is engaged in litigation concerning Evista patents. While optimistic about these defenses, the company acknowledges that unfavorable outcomes could materially impact its financial position.

What is the impact of the new stock-based compensation accounting standard (SFAS 123R) on the company's financial results?

The adoption of SFAS 123R, effective January 1, 2005, requires the expensing of stock options and other stock-based compensation. This accounting change resulted in increased expenses and a reduction in net income. For the third quarter of 2005, net income was reduced by $0.05 per share, and for the first nine months of 2005, it was reduced by $0.16 per share, compared to what would have been reported under the previous accounting methods.

How is the company's sales performance segmented, and which product categories are showing the most growth?

Eli Lilly operates in one primary segment: pharmaceutical products, with animal health as a smaller, included segment. For the third quarter of 2005, Neurosciences and Endocrinology showed strong sales. Notable growth drivers mentioned include Cymbalta, Alimta, Forteo, and Gemzar. New product launches and expanded indications for existing drugs are contributing to sales growth.

LLY 10-Q Quarterly Report Q3 FY2005 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company's third-quarter 2005 report (filed November 3, 2005) shows a 10% increase in worldwide sales to $3.60 billion, driven by strong performance in key product categories like Neurosciences and Endocrinology, and new product launches such as Cymbalta. Net income for the quarter rose 5% to $794.4 million, or $0.73 per share, compared to the prior year. However, the nine-month period reflects a significant 29% decrease in net income to $1.28 billion ($1.17 per share), largely due to a substantial $1.07 billion pre-tax charge recorded in the second quarter related to the Zyprexa product liability settlement. The company is navigating substantial legal challenges, most notably the Zyprexa product liability litigation, for which a master settlement agreement was reached in 2005 covering a majority of claims. While the company is confident in its position regarding patent disputes for key products like Zyprexa and Evista, potential unfavorable outcomes could materially impact financial results. The adoption of SFAS 123R, requiring expensing of stock options, also impacted reported earnings, reducing net income by $0.05 per share for the quarter and $0.16 per share for the nine-month period compared to previous accounting methods.

Key Highlights

1Q3 2005 worldwide sales increased 10% year-over-year to $3.60 billion, driven by strong performance in Neurosciences and Endocrinology categories.
2Q3 2005 net income grew 5% to $794.4 million ($0.73 per share), reflecting sales growth and improved cost management.
3Nine-month 2005 net income decreased 29% to $1.28 billion ($1.17 per share) primarily due to a $1.07 billion pre-tax charge for Zyprexa product liability settlement.
4A master settlement agreement was reached for the majority of U.S. Zyprexa product liability claims, involving a $700 million settlement fund.
5Company is actively defending against generic challenges to patents for Zyprexa and Evista, with ongoing litigation for both products.
6Adoption of SFAS 123R for stock-based compensation increased expenses, reducing net income by $0.05 per share in Q3 and $0.16 per share for the nine-month period.
7Significant investments in research and development continue, with R&D expenses increasing 15% in Q3 and 12% for the nine-month period.

ELI LILLY & Co Quarterly Report for Q3 Ended Sep 30, 2005

Summary

Key Highlights

Frequently Asked Questions